Altamira Therapeutics Ltd - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CYTO Nasdaq 8731 https://aurismedical.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Altamira Therapeutics Ltd

Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis - Sep 14th, 2023 12:47 pm
Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results - Sep 12th, 2023 11:30 am
Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th - Sep 6th, 2023 12:47 pm
Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13 - Aug 23rd, 2023 12:47 pm
Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in Scandinavia - Jul 20th, 2023 12:47 pm
Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed Journal - Jul 17th, 2023 12:47 pm
Altamira Therapeutics Announces Pricing of $5.0 Million Public Offering - Jul 6th, 2023 12:00 pm
Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration - Jul 5th, 2023 12:47 pm
Altamira Therapeutics Announces IND Clearance by U.S. FDA for AM-125 in Acute Vestibular Syndrome - Jun 15th, 2023 12:47 pm
Altamira Therapeutics Announces Publication of Peer-Reviewed Article on Peptide-Based RNA Delivery for Extrahepatic Targets - May 31st, 2023 8:30 pm
Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis - May 24th, 2023 12:47 pm
Altamira Therapeutics Provides Business Update, Reports FY 2022 Financial Results - May 16th, 2023 11:30 am
Altamira Therapeutics to Host Fiscal Year 2022 Financial Results and Business Update Call on May 16th 2023 - May 12th, 2023 12:47 pm
Sidoti's Micro-Cap Virtual May Conference - May 9th, 2023 11:15 am
Altamira Therapeutics CEO & Chairman to Present at Sidoti Micro-Cap Virtual Conference May 10-11 - May 1st, 2023 12:47 pm
Altamira Therapeutics Announces Publication of Positive Results from Phase 2 Trial with AM-125 in Acute Vestibular Syndrome in Leading Peer Reviewed Journal - Apr 12th, 2023 1:30 pm
Altamira Therapeutics Positions its Patented SemaPhore mRNA Delivery Platform as Versatile and Efficient Alternative to Lipid Nanoparticles - Apr 11th, 2023 1:58 pm
Altamira Therapeutics Reports Positive Conclusions from Independent Meta-Analysis of Clinical Studies with Betahistine in Treatment of Most Common Cause of Vertigo - Apr 10th, 2023 12:47 pm
Altamira Therapeutics’ SemaPhore Delivery Platform Shows Significant Synergis-tic Effects of ZBTB46 mRNA with PD1 Immunotherapy in Control of Tumor Growth in Animal Model - Mar 22nd, 2023 12:47 pm
Altamira Therapeutics’ SemaPhore RNA Delivery Platform Drives Effective Treatment of Osteoarthritis with mRNA in Animal Model - Mar 15th, 2023 12:47 pm